J Drugs Dermatol. 2021 Jan 1;20(1):55-61. doi: 10.36849/JDD.5701.
Hair loss is a complex and multi-factorial problem that is associated with significant psychological morbidity in women. Menopausal women represent a significant percentage of those affected, since the menopausal hormonal transition can be a contributing factor. A novel nutraceutical supplement has been specifically formulated with phytoactives to improve hair growth and quality in menopausal women (Nutrafol® Women’s Balance Capsules). The objective of this 6-month, randomized, double-blind, placebo-controlled study was to assess the safety and efficacy of this oral supplement to promote hair growth in perimenopausal, menopausal, and postmenopausal women with self-perceived thinning. Subjects were randomized to the study supplement (n=40) or placebo (n=30). The primary endpoint was a statistically significant increase in the number of terminal and vellus hairs based on phototrichogram analysis. Daily intake of the nutraceutical supplement resulted in progressive and significant increase in terminal and total hair counts on days 90 (P<0.01) and 180 (P<0.01) compared to placebo. The vellus hair counts significantly increased for the active treatment group (P<0.05) by day 180 while significantly decreasing for the placebo group subjects. Hair shedding progressively and significantly decreased for the active group compared to placebo, culminating in a reduction of 32.41% by day 180 (P<0.01). The study supplement was well-tolerated. ClinicalTrials.gov Identifier: NCT04048031 J Drugs Dermatol. 2021;20(1):55-61. doi:10.36849/JDD.5701 THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE. PLEASE SCROLL DOWN TO ACCESS THE FULL TEXT OF THIS ARTICLE WITHOUT LOGGING IN. NO PURCHASE NECESSARY. PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS.
脱发是一个复杂的多因素问题，与女性的显著心理病态有关。更年期女性是受影响的一个重要人群，因为更年期的激素变化可能是一个促成因素。一种新型的营养补充剂专门用植物活性物质配制而成，用于改善更年期妇女的头发生长和质量（Nutrafol® Women’s Balance Capsules）。这项为期 6 个月的、随机的、双盲的、安慰剂对照研究的目的是评估这种口服补充剂的安全性和有效性，以促进有自我感知稀疏的围绝经期、绝经和绝经后妇女的头发生长。受试者被随机分配到研究补充剂（n=40）或安慰剂（n=30）组。主要终点是基于毛发纤维镜分析的终端和毳毛数量的统计学显著增加。与安慰剂相比，营养补充剂的每日摄入导致终端和总发量计数在第 90 天（P<0.01）和第 180 天（P<0.01）的逐渐显著增加。与安慰剂组相比，活跃治疗组的毳毛计数在第 180 天显著增加（P<0.05），而安慰剂组的毳毛计数则显著减少。与安慰剂组相比，活跃组的头发脱落逐渐显著减少，到第 180 天减少了 32.41%（P<0.01）。研究补充剂耐受良好。临床试验注册号：NCT04048031 J 皮肤病药物杂志。2021;20(1):55-61. doi:10.36849/JDD.5701 本文已免费提供。请向下滚动以访问本文的全文，而无需登录。无需购买。如有任何问题，请与出版商联系。
